JB Pharma reports revenue growth of 14% in Q3 FY25; Net profit up by 22%
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
EBITDA rose to Rs. 14.8 crore, marking a 16.5% y-o-y increase, while net profit surged to Rs. 6.4 crore
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
Such combined efficacy (achieving clinical cure and microbiologic cure) of Zaynich is highest ever among all the FDA-approved novel antibiotics developed in the last more than 10 years
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
Subscribe To Our Newsletter & Stay Updated